**BREAKING NEWS** Little Known Biotech Shatters q4 Earnings!

(OTC:BSEM) Just Drooped another Massive Piece of HUGE news The company just reported $11.5 Million in Q4 Revs!!!! Financial updates for the year and quarter ended December 31, 2023: Preliminary net revenue for the fourth quarter 2023 was $11.5 million, (UNAUDITED) an increase of 1,351% from the same period in 2022. Total preliminary net revenue reached $16.7 million (UNAUDITED), in the fiscal year concluding on December 31, 2023, representing a 142% increase compared to the previous year. With earnings blowing past expectations and a $9.25 Zacks price target, this biotech company could be ready for BLUE-SKY growth ahead. The biotech arena is home to giants like Merck and Pfizer, but it's also home to many emerging companies that offer tremendous upside potential. One company in particular has been making waves in headlines recently after reporting a blowout third quarter and getting a nearly $10 price target from Zack's Small Cap Research! Milestones continue to add up for the company which is on a mission to advance and develop its cutting-edge placental-derived allografts for advanced wound care. This growing company is falling under the radar but could soon hit the spotlight for its role in the diabetes care market. How? The Company harnesses the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company is focused on manufacturing products that change lives, leveraging its proprietary processing method. Not long ago the company was awarded a Q code for one of its products by the Centers for Medicare and Medicaid Services. (CMS). This is a huge milestone and will be effective on January 1st! Zacks Smallcap Research noted: "With the company's recent announcement of a Q code, we believe rapid growth is set to continue and are raising our valuation level as a result." Discovery why Zack's thinks this company is 'still underpriced' and why it may see big gains ahead.

---

This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).

Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.

StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com